Preclinical studies have demonstrated that selenium compounds, especially in their organoselenium forms such as methylselenocysteine and seleno-L-methionine, can sensitize breast cancer cells to standard chemotherapeutic agents by enhancing oxidative stress and disrupting survival signaling pathways like PI3K/Akt and MAPK/ERK[50]. This evidence concerns the gene AKT1 and breast carcinoma.